Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

PRME

Prime Medicine Inc

May 17 • 04:00PM ET

7.08

Dollar change +0.04
Percentage change 0.57	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: ARKG ARKK VTI VB IWM VBK VXF IBB IWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-2.13	Insider Own	58.50%	Shs Outstand	97.38M	Perf Week	26.20%
Market Cap	849.81M	Forward P/E	-	EPS next Y	-1.51	Insider Trans	15.84%	Shs Float	49.81M	Perf Month	54.25%
Income	-204.50M	PEG	-	EPS next Q	-0.39	Inst Own	34.64%	Short Float	21.84%	Perf Quarter	-16.31%
Sales	0.59M	P/S	1440.36	EPS this Y	24.26%	Inst Trans	-	Short Ratio	15.16	Perf Half Y	8.59%
Book/sh	2.03	P/B	3.49	EPS next Y	8.76%	ROA	-65.09%	Short Interest	10.88M	Perf Year	-45.62%
Cash/sh	1.76	P/C	4.03	EPS next 5Y	-	ROE	-78.27%	52W Range	4.11 - 17.20	Perf YTD	-20.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-193.88%	ROI	-72.82%	52W High	-58.84%	Beta	2.49
Dividend TTM	-	Quick Ratio	8.91	Sales past 5Y	-25.00%	Gross Margin	-1850.08%	52W Low	72.26%	ATR (14)	0.53
Dividend Ex-Date	Sep 10, 2019	Current Ratio	8.91	EPS Y/Y TTM	-33.33%	Oper. Margin	-33773.27%	RSI (14)	68.77	Volatility	9.23% 9.62%
Employees	234	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-34601.86%	Recom	1.36	Target Price	14.60
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	0.97%	Payout	-	Rel Volume	0.85	Prev Close	7.04
Sales Surprise	-69.25%	EPS Surprise	3.28%	Sales Q/Q	-	Earnings	May 10 BMO	Avg Volume	717.54K	Price	7.08
SMA20	30.74%	SMA50	15.81%	SMA200	-14.01%	Trades		Volume	610,161	Change	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27
Nov-14-22	Initiated	Jefferies	Buy	$25
Nov-14-22	Initiated	Goldman	Neutral	$22

Show Previous Ratings

May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-16-24 07:14AM	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target (MT Newswires)
May-14-24 09:55AM	Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect? (Zacks)
May-13-24 11:12AM	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating (MT Newswires) +14.44%
08:00AM	Loading…
08:00AM	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-12-24 03:00AM	Alphabet Bought Up Two Slumping Stocks (Barrons.com)
May-10-24 02:23PM	Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments (GuruFocus.com)
01:53PM	PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-08-24 08:00AM	Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
May-03-24 12:00PM	What Makes Prime Medicine, Inc. (PRME) a New Buy Stock (Zacks)
May-01-24 08:00AM	Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference (GlobeNewswire) +7.11%
Apr-30-24 06:01AM	Prime Medicine gets green light for trials of first-ever prime editing drug (Clinical Trials Arena)
Apr-29-24 10:12AM	Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance (MT Newswires) +9.83%
07:35AM	Loading…
07:35AM	Prime gets FDA green light to begin first trial test of prime editing (BioPharma Dive)
07:33AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
Apr-23-24 08:00AM	Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 08:45AM	2 Magnificent Growth Stocks With Room to Run (Motley Fool)
Mar-14-24 02:44PM	Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging (InvestorPlace) -13.18%
Mar-01-24 02:00PM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? (InvestorPlace)
08:00AM	Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) -5.99%
Feb-28-24 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:01PM	Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.08%
Feb-14-24 11:50PM	Prime Medicine Announces Pricing of Upsized Public Offering (GlobeNewswire)
04:05PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-01-24 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) +5.67%
Jan-25-24 08:00AM	Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE Prime Editors for Cystic Fibrosis (GlobeNewswire)
06:21PM	Loading…
Jan-09-24 06:21PM	Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know (Zacks)
Jan-05-24 05:00PM	Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes (PR Newswire)
08:00AM	Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer (GlobeNewswire)
Jan-02-24 08:00AM	Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-23 10:30AM	Better Growth Stock: Archer Aviation or Prime Medicine? (Motley Fool) +6.73%
Nov-30-23 07:45AM	1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years (Motley Fool)
Nov-08-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire) -9.75%
Nov-03-23 04:01PM	Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +17.65%
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 06:00AM	Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b (GlobeNewswire) -6.60%
Oct-24-23 07:30AM	Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases (GlobeNewswire)
05:04AM	The Bull Market Can Continue to Roll On; BMOs Brian Belski Predicts Further Gains for Stocks Here Are 3 Names to Play That Bullish Sentiment (TipRanks)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 08:00AM	Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences (GlobeNewswire) +10.00%
Oct-09-23 09:33AM	Oracle upgraded, Spotify downgraded: Wall Street's top analyst calls (The Fly)
Sep-19-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-31-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-07-23 04:01PM	Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -8.66%
Jul-25-23 07:45AM	2 Cathie Wood Stocks That Could Be Hidden Gems (Motley Fool)
Jun-29-23 08:46AM	We're Hopeful That Prime Medicine (NASDAQ:PRME) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-23 08:00AM	Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome (GlobeNewswire)
Jun-02-23 10:15AM	Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought (Motley Fool) +9.15%
May-31-23 08:00AM	Prime Medicine to Present at Investor Conferences in June (GlobeNewswire)
May-26-23 09:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
May-17-23 04:05PM	Prime Medicine to Present at Virtual Investor Conferences in May (GlobeNewswire)
06:00AM	Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting (GlobeNewswire)
May-11-23 08:00AM	Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -10.61%
Mar-27-23 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days (GlobeNewswire) +5.89%
Mar-09-23 08:00AM	Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-23 08:00AM	Prime Medicine to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Jan-20-23 05:56AM	We Think Prime Medicine (NASDAQ:PRME) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-09-23 07:00AM	Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities (GlobeNewswire)
Jan-03-23 08:00AM	Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.60%
Nov-01-22 04:13PM	After Prime Medicine, What's the Next Gene Editing IPO? (TheStreet.com) +12.22%
Oct-24-22 05:30PM	Prime Medicine Announces Closing of Upsized Initial Public Offering (GlobeNewswire)
Oct-20-22 12:45PM	UPDATE 1-Biotech firm Prime Medicine valued at $1.8 bln in strong debut (Reuters)
Oct-19-22 09:47PM	Prime Medicine Announces Pricing of Upsized Initial Public Offering (Business Wire)

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARCH Venture Partners XII, LLC	10% Owner	Feb 15 '24	Buy	6.25	3,200,000	20,000,000	3,200,000	Feb 20 05:38 PM
ARCH Venture Partners X, LLC	10% Owner	Feb 15 '24	Buy	6.25	3,200,000	20,000,000	3,200,000	Feb 20 05:37 PM
NELSEN ROBERT	Director	Feb 15 '24	Buy	6.25	3,200,000	20,000,000	3,200,000	Feb 20 05:41 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 21 '23	Sale	14.97	19,003	284,496	0	Jun 22 05:03 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 20 '23	Sale	15.06	37,405	563,248	0	Jun 22 05:03 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 16 '23	Sale	15.02	6,532	98,109	0	Jun 20 04:17 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 15 '23	Sale	14.92	66,659	994,326	0	Jun 20 04:17 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 14 '23	Sale	14.87	28,960	430,684	0	Jun 15 04:22 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 13 '23	Sale	15.13	28,100	425,102	0	Jun 15 04:22 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 12 '23	Sale	14.98	16,031	240,151	0	Jun 13 04:20 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 09 '23	Sale	14.48	15,672	226,984	0	Jun 13 04:20 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 08 '23	Sale	15.74	5,000	78,686	0	Jun 09 04:24 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 07 '23	Sale	16.92	15,000	253,871	0	Jun 09 04:24 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 06 '23	Sale	17.02	29,975	510,166	0	Jun 07 04:17 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 05 '23	Sale	16.70	22,434	374,612	0	Jun 07 04:17 PM
GV 2019 GP, L.L.C.	10% Owner	Jun 01 '23	Sale	14.36	45,223	649,194	0	Jun 02 04:17 PM
GV 2019 GP, L.L.C.	10% Owner	May 31 '23	Sale	13.65	16,633	227,004	0	Jun 02 04:17 PM
GV 2019 GP, L.L.C.	10% Owner	May 30 '23	Sale	13.70	16,805	230,240	0	May 31 04:15 PM
GV 2019 GP, L.L.C.	10% Owner	May 26 '23	Sale	13.70	12,602	172,603	0	May 31 04:15 PM
GV 2019 GP, L.L.C.	10% Owner	May 25 '23	Sale	13.38	23,161	309,973	0	May 26 04:17 PM
GV 2019 GP, L.L.C.	10% Owner	May 24 '23	Sale	13.66	7,900	107,920	0	May 26 04:17 PM
GV 2019 GP, L.L.C.	10% Owner	May 23 '23	Sale	14.74	43,939	647,648	0	May 24 05:07 PM
GV 2019 GP, L.L.C.	10% Owner	May 22 '23	Sale	14.13	87,922	1,242,092	0	May 24 05:07 PM
GV 2019 GP, L.L.C.	10% Owner	May 19 '23	Sale	13.88	63,212	877,066	0	May 22 04:21 PM

Open in Screener

SANA

Sana Biotechnology Inc

May 17 • 04:00PM ET

8.73

Dollar change +0.18
Percentage change 2.11	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VBK VXF IWN IBB SCHA LABU VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.53	Insider Own	45.81%	Shs Outstand	197.86M	Perf Week	15.48%
Market Cap	1.93B	Forward P/E	-	EPS next Y	-1.12	Insider Trans	5.57%	Shs Float	120.04M	Perf Month	12.94%
Income	-308.61M	PEG	-	EPS next Q	-0.28	Inst Own	50.30%	Short Float	21.37%	Perf Quarter	0.58%
Sales	0.00M	P/S	-	EPS this Y	16.16%	Inst Trans	1.60%	Short Ratio	13.36	Perf Half Y	105.90%
Book/sh	1.70	P/B	5.15	EPS next Y	8.35%	ROA	-43.21%	Short Interest	25.65M	Perf Year	16.71%
Cash/sh	1.42	P/C	6.14	EPS next 5Y	-	ROE	-76.82%	52W Range	2.74 - 12.00	Perf YTD	113.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-83.13%	ROI	-65.93%	52W High	-27.25%	Beta	1.57
Dividend TTM	-	Quick Ratio	6.07	Sales past 5Y	0.00%	Gross Margin	-	52W Low	218.03%	ATR (14)	0.71
Dividend Ex-Date	-	Current Ratio	6.07	EPS Y/Y TTM	9.45%	Oper. Margin	0.00%	RSI (14)	49.23	Volatility	8.28% 8.03%
Employees	328	Debt/Eq	0.28	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.80	Target Price	12.00
Option/Short	Yes / Yes	LT Debt/Eq	0.25	EPS Q/Q	-15.18%	Payout	-	Rel Volume	0.66	Prev Close	8.55
Sales Surprise	-	EPS Surprise	-62.52%	Sales Q/Q	-	Earnings	May 08 AMC	Avg Volume	1.92M	Price	8.73
SMA20	-0.95%	SMA50	-2.91%	SMA200	45.13%	Trades		Volume	1,264,807	Change	2.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Sep-25-23	Initiated	JMP Securities	Mkt Outperform	$9
Sep-05-23	Initiated	Citigroup	Buy	$8
Aug-14-23	Initiated	TD Cowen	Market Perform
May-02-23	Initiated	H.C. Wainwright	Neutral
Mar-01-21	Initiated	Morgan Stanley	Overweight	$40
Mar-01-21	Initiated	JP Morgan	Neutral	$35
Mar-01-21	Initiated	Goldman	Neutral	$40
Mar-01-21	Initiated	BofA Securities	Buy	$45

May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia) -7.77%
May-10-24 01:35PM	Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire) -20.97%
May-08-24 10:55PM	SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024 (InvestorPlace) -5.48%
05:22PM	Sana: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
May-06-24 04:05PM	Sana Biotechnology to Present at May and June 2024 Investor Conferences (GlobeNewswire)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-19-24 10:00AM	CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) (GlobeNewswire)
08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Mar-11-24 07:00PM	Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA) (GuruFocus.com)
Mar-07-24 09:01AM	Baillie Gifford Bolsters Stake in Sana Biotechnology Inc (GuruFocus.com)
Feb-29-24 04:55PM	Sana: Q4 Earnings Snapshot (Associated Press Finance) -5.90%
04:05PM	Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
04:05PM	Loading…
Feb-28-24 04:05PM	Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference (GlobeNewswire) +7.34%
Feb-13-24 04:05PM	Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP (GlobeNewswire)
Feb-12-24 04:05PM	Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-08-24 01:22AM	Sana Biotechnology Announces Pricing of Upsized Public Offering (GlobeNewswire)
Feb-07-24 04:01PM	Sana Biotechnology Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-27-24 11:02AM	Baillie Gifford Reduces Stake in Sana Biotechnology Inc (GuruFocus.com)
Jan-18-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice (Zacks) -7.68%
10:24AM	Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why (Zacks)
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire)
Jan-08-24 06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire)
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-05-24 09:00AM	Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies (GlobeNewswire)
Jan-03-24 04:05PM	Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +11.90%
Dec-19-23 09:01AM	EVP Christian Hordo Sells 75,000 Shares of Sana Biotechnology Inc (SANA) (GuruFocus.com) +13.60%
Dec-11-23 09:00AM	Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting (GlobeNewswire)
04:05PM	Loading…
Dec-01-23 04:05PM	Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System (GlobeNewswire)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
Nov-21-23 09:00AM	Sana Biotechnology to Present at November and December 2023 Investor Conferences (GlobeNewswire) -6.74%
06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire)
Nov-17-23 09:00AM	Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes (GlobeNewswire) +7.14%
Nov-09-23 04:05PM	Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis (GlobeNewswire)
Nov-08-23 04:05PM	Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire) -13.92%
Nov-02-23 09:05AM	Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire)
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire)
Oct-10-23 04:15PM	Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M (GlobeNewswire)
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire) -7.49%
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire) +5.31%
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Aug-30-23 04:05PM	Sana Biotechnology to Present at September 2023 Investor Conferences (GlobeNewswire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-03-23 05:03PM	Sana: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jun-16-23 09:00AM	Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting (GlobeNewswire)
May-31-23 04:05PM	Sana Biotechnology to Present at June 2023 Investor Conferences (GlobeNewswire)
May-22-23 07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com) +5.76%
May-16-23 06:00AM	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry (PR Newswire)
May-08-23 04:35PM	Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional (GlobeNewswire)
04:26PM	Sana: Q1 Earnings Snapshot (AP Finance)
04:05PM	Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
May-04-23 01:56PM	7 High-Potential Penny Stocks in the Biotech Sector (InvestorPlace)
May-03-23 04:05PM	Sana Biotechnology to Present at May 2023 Investor Conferences (GlobeNewswire) +8.91%
09:55AM	Wall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to Trade (Zacks)
May-02-23 04:30PM	Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire) -7.68%
12:50PM	Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth? (Simply Wall St.)
Apr-24-23 04:05PM	Sana Biotechnology to Host Research & Development Day (GlobeNewswire)
Apr-20-23 10:07AM	The Top 3 Biotech Stocks to Watch in 2023 (InvestorPlace) -8.59%
Apr-19-23 04:05PM	Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-17-23 09:55AM	Does Sana (SANA) Have the Potential to Rally 78.23% as Wall Street Analysts Expect? (Zacks) +8.67%
06:17AM	2 Growth Stocks That Jumped 42% and 58% Last Week: Can They Still Climb Higher? (Motley Fool)
Apr-14-23 10:27AM	Why Shares of Sana Biotechnology Jumped This Week (Motley Fool) +5.92%
Apr-13-23 09:00AM	Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses (GlobeNewswire) +30.67%
Apr-12-23 04:05PM	Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model (GlobeNewswire)
Apr-10-23 04:05PM	Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization (GlobeNewswire)
Mar-24-23 03:20PM	Jeff Bezos Stock Portfolio: 10 Companies and Startups (Insider Monkey)
Mar-16-23 04:05PM	Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Mar-14-23 04:53PM	Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-01-23 04:05PM	Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-10-23 08:18AM	Insiders who purchased this year lose US$82k as Sana Biotechnology, Inc. (NASDAQ:SANA) stock drops to US$4.36 (Simply Wall St.)
Feb-02-23 04:05PM	Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference (GlobeNewswire)
Jan-26-23 04:05PM	Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies (GlobeNewswire)
Jan-03-23 04:05PM	Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.57%
Dec-11-22 05:30PM	Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting (GlobeNewswire)
Dec-01-22 12:11AM	Sana Biotechnology to lay off 15% of its employees (American City Business Journals) -11.22%
Nov-30-22 10:55AM	Once valued at $6 billion, Sana Biotechnology plans to cut 15% of workforce (American City Business Journals) +5.94%
08:43AM	Sana Biotechnology Outlines Pipeline Prioritization, Reduces Workforce (Benzinga)
Nov-29-22 04:05PM	Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization (GlobeNewswire)
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies (Insider Monkey)
Nov-14-22 04:05PM	Sana Biotechnology Tops BioSpaces 2023 Best Places to Work Ranking in Small Employer Category (GlobeNewswire)
Nov-03-22 09:07AM	Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting (GlobeNewswire) -13.94%
Nov-02-22 04:05PM	Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
Oct-18-22 07:43AM	We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate (Simply Wall St.)
Sep-09-22 04:05PM	Sana Biotechnology to Present at September 2022 Investor Conferences (GlobeNewswire)
Sep-03-22 08:39AM	Insiders who bought in the last 12 months lose an additional US$22k as Sana Biotechnology, Inc. (NASDAQ:SANA) drops to US$1.2b (Simply Wall St.)
Aug-09-22 11:54AM	7 Stocks Due for a Stunning Short Squeeze (InvestorPlace) -6.90%
Aug-04-22 04:05PM	Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +10.10%
Jun-17-22 09:00AM	Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates (GlobeNewswire) +21.46%
Jun-13-22 04:05PM	Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting (GlobeNewswire) -10.54%
Jun-07-22 04:05PM	Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire) +5.45%
Jun-02-22 01:55AM	Sana Biotechnology to develop manufacturing facility in Bothell (American City Business Journals) +9.26%
Jun-01-22 04:05PM	Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory (GlobeNewswire)
May-12-22 05:40PM	Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorados Gates Institute (GlobeNewswire) -10.56%
May-11-22 07:19AM	We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate (Simply Wall St.) -13.46%
May-10-22 04:05PM	Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +9.09%
May-04-22 04:05PM	Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire) +8.56%

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yang Patrick Y	Director	Mar 08 '24	Sale	9.45	25,000	236,300	149,250	Mar 11 04:57 PM
NELSEN ROBERT	Director	Feb 08 '24	Buy	5.50	1,818,181	9,999,996	12,446,022	Feb 12 05:46 PM
ARCH Venture Fund X, L.P.	10% Owner	Feb 08 '24	Buy	5.50	1,818,181	9,999,996	12,446,022	Feb 12 05:43 PM
CRANDELL KEITH	10% Owner	Feb 08 '24	Buy	5.50	1,818,181	9,999,996	12,446,022	Feb 12 05:43 PM
Hordo Christian	EVP, Chief Business Officer	Dec 15 '23	Sale	4.00	75,000	300,098	867,455	Dec 18 04:51 PM
Flagship Ventures Fund V Gener	10% Owner	Jun 07 '23	Sale	6.24	200,000	1,247,940	1,380,277	Jun 08 07:00 PM
Flagship Ventures Fund V Gener	10% Owner	Jun 06 '23	Sale	6.31	203,758	1,284,918	1,403,037	Jun 08 07:00 PM
Flagship Ventures Fund V Gener	10% Owner	May 26 '23	Sale	6.23	82,000	510,573	1,425,334	May 26 08:00 PM
Flagship Ventures Fund V Gener	10% Owner	May 25 '23	Sale	6.35	115,372	732,866	1,434,664	May 26 08:00 PM
Flagship Ventures Fund V Gener	10% Owner	May 24 '23	Sale	6.57	347,870	2,283,836	1,447,791	May 26 08:00 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PRME

Prime Medicine Inc

SANA

Sana Biotechnology Inc

Upgrade your FINVIZ experience